JP2018503355A5 - - Google Patents

Download PDF

Info

Publication number
JP2018503355A5
JP2018503355A5 JP2017523423A JP2017523423A JP2018503355A5 JP 2018503355 A5 JP2018503355 A5 JP 2018503355A5 JP 2017523423 A JP2017523423 A JP 2017523423A JP 2017523423 A JP2017523423 A JP 2017523423A JP 2018503355 A5 JP2018503355 A5 JP 2018503355A5
Authority
JP
Japan
Prior art keywords
fusion protein
seq
protein according
motomeko
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017523423A
Other languages
English (en)
Japanese (ja)
Other versions
JP6740225B2 (ja
JP2018503355A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/058521 external-priority patent/WO2016070156A2/en
Publication of JP2018503355A publication Critical patent/JP2018503355A/ja
Publication of JP2018503355A5 publication Critical patent/JP2018503355A5/ja
Application granted granted Critical
Publication of JP6740225B2 publication Critical patent/JP6740225B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017523423A 2014-10-31 2015-10-31 Ｃ１エステラーゼ阻害因子融合タンパク質及びその使用 Active JP6740225B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462073657P 2014-10-31 2014-10-31
US62/073,657 2014-10-31
PCT/US2015/058521 WO2016070156A2 (en) 2014-10-31 2015-10-31 C1 esterase inhibitor fusion proteins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020125041A Division JP2020202841A (ja) 2014-10-31 2020-07-22 Ｃ１エステラーゼ阻害因子融合タンパク質及びその使用

Publications (3)

Publication Number Publication Date
JP2018503355A JP2018503355A (ja) 2018-02-08
JP2018503355A5 true JP2018503355A5 (https=) 2018-12-13
JP6740225B2 JP6740225B2 (ja) 2020-08-12

Family

ID=54548264

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017523423A Active JP6740225B2 (ja) 2014-10-31 2015-10-31 Ｃ１エステラーゼ阻害因子融合タンパク質及びその使用
JP2020125041A Withdrawn JP2020202841A (ja) 2014-10-31 2020-07-22 Ｃ１エステラーゼ阻害因子融合タンパク質及びその使用
JP2022200230A Withdrawn JP2023027290A (ja) 2014-10-31 2022-12-15 Ｃ１エステラーゼ阻害因子融合タンパク質及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020125041A Withdrawn JP2020202841A (ja) 2014-10-31 2020-07-22 Ｃ１エステラーゼ阻害因子融合タンパク質及びその使用
JP2022200230A Withdrawn JP2023027290A (ja) 2014-10-31 2022-12-15 Ｃ１エステラーゼ阻害因子融合タンパク質及びその使用

Country Status (10)

Country Link
US (1) US20160130324A1 (https=)
EP (2) EP3769780A1 (https=)
JP (3) JP6740225B2 (https=)
KR (2) KR102753264B1 (https=)
CN (2) CN107108753A (https=)
AU (2) AU2015338913B2 (https=)
BR (1) BR112017008962A2 (https=)
CA (1) CA2964132A1 (https=)
MA (1) MA53991A (https=)
WO (1) WO2016070156A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3005906A1 (en) 2015-11-19 2017-05-26 Shire Human Genetic Therapies, Inc. Recombinant human c1 esterase inhibitor and uses thereof
AU2017316513A1 (en) 2016-08-23 2019-03-28 Csl Behring Gmbh Method of preventing acute attacks of hereditary angioedema associated with C1 esterase inhibitor deficiency
AU2018281337B2 (en) 2017-06-06 2022-08-25 Relinia, Inc. Single-chain TNF receptor 2 agonist fusion proteins
AU2018288030B2 (en) * 2017-06-20 2022-02-03 Systimmune, Inc. Screening of fixed-point coupling sites of cysteine-modified antibody-toxin conjugate (TDC)
EP3866860B1 (en) * 2018-10-15 2025-01-08 The Regents Of The University Of California Complement component 1s (c1s) deficient cells for production of vaccines and biopharmaceutical proteins
US20230038502A1 (en) * 2019-06-11 2023-02-09 Shire Human Genetic Therapies, Inc. Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein
CN111087475B (zh) * 2019-12-25 2022-07-08 东莞市东阳光生物药研发有限公司 Fgf21融合蛋白及抑制其降解的方法
CN113493519B (zh) * 2020-03-19 2022-12-27 浙江道尔生物科技有限公司 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白
AU2021381360A1 (en) 2020-11-20 2023-06-22 Csl Behring Gmbh Method for treating antibody-mediated rejection
WO2025072726A1 (en) 2023-09-29 2025-04-03 Trex Bio, Inc. Tnf-alpha variant fusion molecules

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US5149636A (en) 1982-03-15 1992-09-22 Trustees Of Columbia University In The City Of New York Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5096816A (en) 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
FR2672895B1 (fr) 1991-02-15 1995-05-12 Transgene Sa Procede de purification d'une proteine fortement glycosylee.
WO1992022320A1 (en) * 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
HUP0204475A2 (en) * 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
EP2206720A1 (en) * 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
PT1355919E (pt) * 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
CA2492267C (en) 2002-07-15 2013-09-10 Immunex Corporation Methods and media for controlling sialylation of proteins produced by mammalian cells
US8524477B2 (en) 2002-10-29 2013-09-03 Crucell Holland B.V. Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
US7384754B2 (en) 2003-10-31 2008-06-10 Agilent Technologies, Inc. Enrichment and tagging of glycosylated proteins
AU2005271403A1 (en) * 2004-08-03 2006-02-16 Biorexis Pharmaceutical Corporation Combination therapy using transferrin fusion proteins comprising GLP-1
GB0507123D0 (en) 2005-04-08 2005-05-11 Isis Innovation Method
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
EP3026109B1 (en) 2005-12-08 2022-03-09 Amgen Inc. Improved production of glycoproteins using manganese
EP2623986B1 (en) 2006-02-10 2017-06-14 Life Technologies Corporation Labeling and detection of post translationally modified proteins
WO2008025856A2 (en) 2006-09-01 2008-03-06 Novo Nordisk Health Care Ag Modified glycoproteins
IL182956A0 (en) 2007-05-03 2008-01-20 Yeda Res & Dev Glycan modified soluble receptors and binding proteins and their use
CN101896616B (zh) 2007-10-12 2014-06-04 西格马-奥利奇股份有限公司 提高糖蛋白唾液酸化作用的组合物与方法
WO2009104199A1 (en) 2008-02-19 2009-08-27 Biocon Limited A method of obtaining purified heterologous insulins expressed in yeast
EP2166085A1 (en) 2008-07-16 2010-03-24 Suomen Punainen Risti Veripalvelu Divalent modified cells
CN102317309A (zh) 2009-02-26 2012-01-11 巴特勒能源同盟有限公司 通过不同的翻译后修饰改变和调节蛋白质活性
ES2688978T3 (es) 2009-11-23 2018-11-07 Amgen Inc. Anticuerpo monomérico Fc
JP5889181B2 (ja) * 2010-03-04 2016-03-22 中外製薬株式会社 抗体定常領域改変体
WO2011116291A1 (en) * 2010-03-18 2011-09-22 Thrombolytic Science International Production of human c1 inhibitor in human cells
US20120010013A1 (en) * 2010-06-19 2012-01-12 Fellows Edwin E Swing assistant device
CA2808154A1 (en) 2010-08-13 2012-02-16 Medimmmune Limited Monomeric polypeptides comprising variant fc regions and methods of use
WO2012083370A1 (en) * 2010-12-22 2012-06-28 Cephalon Australia Pty Ltd Modified antibody with improved half-life
KR20140114276A (ko) 2011-02-10 2014-09-26 라이덴 유니버시티 메디컬 센터 코튼을 포함하는 정지상을 이용하는 크로마토그래피에 의한 글리칸 및/또는 글리코컨쥬게이트의 정제 방법
US8580922B2 (en) 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
SG10201602394QA (en) * 2011-03-29 2016-05-30 Roche Glycart Ag Antibody FC Variants
CN110551223A (zh) * 2011-06-28 2019-12-10 英伊布里克斯有限合伙公司 丝氨酸蛋白酶抑制蛋白融合多肽及其使用方法
BR112014000352A2 (pt) 2011-07-08 2017-02-14 Merck Sharp & Dohe Corp método de purificar uma proteína de fusão-fc, proteínas de fusão contendo fc purificada, tnfr:fc purificada, e tnfr:fc elevadamente purificada
CN102890790B (zh) * 2011-07-22 2014-04-30 鸿富锦精密工业（深圳）有限公司 扩展卡
WO2013093760A2 (en) 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
DK2793935T3 (en) * 2011-12-22 2016-09-05 Csl Behring Gmbh Use of C1 inhibitor in the treatment of secondary edema in the central nervous system.
EP2623110A1 (en) * 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
US9676857B2 (en) 2012-03-16 2017-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Soluble engineered monomeric Fc
JP6396313B2 (ja) 2012-12-07 2018-09-26 ファイザー・インク 操作された単量体抗体断片
CA2901225C (en) * 2013-03-08 2023-09-19 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
US20160184458A1 (en) * 2013-03-14 2016-06-30 Shire Human Genetic Therapies, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
EP2796145B1 (en) * 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge

Similar Documents

Publication Publication Date Title
JP2018503355A5 (https=)
JP7344858B2 (ja) Ｆｃ含有ポリペプチドの安定化
CA2781539C (en) Monomeric antibody fc
EP3576789B1 (en) MONOMERIC HUMAN IgG1 Fc AND BISPECIFIC ANTIBODIES
JP2025026880A (ja) 操作されたＦｃコンストラクトに関する組成物及び方法
EP2985294A1 (en) Recombinant antibody molecule and its use for target cell restricted T cell activation
WO2018032786A1 (zh) 人凝血因子ix融合蛋白及其制备方法与用途
JP2019531087A (ja) 高グリコシル化ヒト血液凝固第ｖｉｉｉ因子の融合タンパク質、その調製方法、および使用
AU2016228806A1 (en) Method of purifying albumin-fusion proteins
AU2020268684A1 (en) Variant domains for multimerizing proteins and separation thereof
WO2020063562A1 (zh) 突变型单链人凝血因子viii融合蛋白及其制备方法与用途
WO2003062370B1 (en) Multimeric proteins and methods of making and using same
JP7638900B2 (ja) 半減期が延長された活性化可能な治療用多重特異性ポリペプチド
JP7688584B2 (ja) ポリペプチド鎖の交換により活性化される治療用多重特異性ポリペプチド
JP2025528213A (ja) 複数ドメイン結合性分子
WO2017009419A1 (en) Bispecific antibody-like molecules having bivalency vis-à-vis each antigen
CN121930334A (zh) 含有Fc的多肽的稳定化